3h
Hosted on MSNBaird Downgrades Maravai LifeSciences Holdings (MRVI)Fintel reports that on February 26, 2025, Baird downgraded their outlook for Maravai LifeSciences Holdings (NasdaqGS:MRVI) ...
Maravai LifeSciences (MRVI) stock was downgraded by Baird based on the company's decision to delay its quarterly earnings report and 10-K. Read more here.
Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ: MRVI) investors concerning the Company's possible ...
In a report released today, Matt Larew from William Blair maintained a Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stock fell 15% after the company announced it is postponing its fourth quarter and full year 2024 earnings release and conference call. The life ...
Maravai LifeSciences (MRVI) shares drop 15% premarket as it postpones 2024 earnings release, citing year-end financial review.
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...
On Tuesday, February 25, 2025, Maravai LifeSciences disclosed that it would be postponing its previously announced earnings release and call scheduled for February 25, 2025, and it would be unable to ...
Maravai LifeSciences Holdings (NASDAQ:MRVI) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is -$0.04 (+95.0% Y/Y) and the ...
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced ...
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results